# Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

> **NCT04720534** · PHASE2 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 229 (actual)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** ARO-APOC3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04720534
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-31
- **Primary completion:** 2023-03-09
- **Final completion:** 2023-08-31
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720534, "Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04720534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*